Clinical trials: Dementia Disorders
Alzheimer Disease
A Safety and Tolerability Study of GB301
The primary objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions at a single dose strength of GB301 in subjects with mild to moderate AD.
- Trial name
- NCT03865017
- Testing
- Regulatory T cells, Saline
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- VTBIO Co. LTD
Alzheimer Disease
A Study of LY3439539 in Participants With Alzheimer's Disease
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.
- Trial name
- NCT07598370
- Testing
- LY3439539
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed…
- Trial name
- NCT02600130
- Testing
- Longeveron Mesenchymal Stem Cells
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Longeveron Inc.
Chorea, Huntington
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Trial name
- NCT04400331
- Testing
- Valbenazine
- Where
- 34 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Neurocrine Biosciences
Alzheimer Disease
Single Ascending Dose Study of SRA-444 in Healthy Subjects
This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending…
- Trial name
- NCT00452504
- Testing
- SRA-444
- Where
- Netherlands
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Alzheimer Disease, Early Onset Alzheimer Disease
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild…
- Trial name
- NCT03634007
- Testing
- LX1001
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lexeo Therapeutics
Alzheimer's Disease
Open Label Study of TRx0014 in Alzheimer's Disease
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001…
- Trial name
- NCT00684944
- Testing
- TRx0014
- Volunteers
- 111 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease, Dementia
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all…
- Trial name
- NCT02004392
- Testing
- EVP-6124
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 348 people
- Sponsor
- FORUM Pharmaceuticals Inc
AIDS Dementia Complex, HIV Infections
Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy
The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the levels of HIV, T cells (cells in the body that…
- Trial name
- NCT00002209
- Testing
- CPI-1189
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Centaur Pharmaceuticals
Alzheimer Disease
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT06881836
- Testing
- ONO-2020
- Where
- 80 sites in United States, Japan
- Volunteers
- 260 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Huntington's Disease
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
- Trial name
- LEGATO-HD (NCT02215616)
- Testing
- Laquinimod
- Where
- 53 sites in United States, Canada and 8 more
- Volunteers
- 352 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Aging, Aging Well
100-Year Human Aging Study
The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo…
- Conditions
- Aging, Aging Well, All-Cause Mortality, Mortality
- Trial name
- NCT07563777
- Testing
- Comprehensive Multi-System Clinical Screening
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Longevity Metrics, Inc.
Alzheimer's Disease
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00112073
- Testing
- bapineuzumab
- Where
- 26 sites in United States
- Volunteers
- 234 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this Phase III study is to evaluate the efficacy and safety of 3APS compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00088673
- Testing
- 3APS
- Where
- 67 sites in United States, Canada
- Volunteers
- 950 people
- Sponsor
- Bellus Health Inc. - a GSK company
Alzheimer's Disease
Evaluation of Physician Training Methods to Read Florbetapir-PET Scans
The purpose of this study is re-read of brain amyloid positron emission tomography (PET) scans acquired in previous florbetapir F 18 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565369
- Testing
- florbetapir F 18
- Volunteers
- 35 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due…
- Trial name
- NCT03901105
- Testing
- flortaucipir F18, Brain PET Scan
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer's disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and…
- Trial name
- NCT02406027
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, JNJ-54861911, 5 mg
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.